Preventing early-onset colorectal tumors with tirzepatide
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests if tirzepatide can help prevent early-onset colorectal tumors in people aged 18-50 who have had certain types of polyps removed. It aims to find risk factors and ways to stop colorectal cancer before it starts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 50 years old.
- Your BMI is between 27 and 40.
- You had a colonoscopy in the last 9 months.
- During that colonoscopy, you had at least 2 adenomas or one adenoma 6mm or larger removed.
- You have never taken a medication like tirzepatide (a GLP-1 drug).
- You do not have diabetes, a history of certain cancers, or a genetic condition that increases colorectal cancer risk.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if tirzepatide, a drug that helps with weight loss, can improve outcomes for women with obesity and certain early-stage endometrial conditions before a planned hysterectomy.
This trial tests the weight‑loss medication tirzepatide (Mounjaro) in people who are overweight or have obesity and have stable coronary artery disease. The goal is to see if tirzepatide can reduce dangerous fatty plaque in heart arteries.
This study tests whether the weight-loss drug tirzepatide (Mounjaro) can help prevent breast cancer from coming back in people who are overweight and have a sign of leftover cancer cells in their blood (called MRD-positive). You must have already finished at least one year of hormone therapy for early-stage breast cancer.
This trial tests if tirzepatide, a weight-loss medication, can help postmenopausal women with hormone-positive breast cancer who have obesity. It aims to improve health outcomes after completing cancer treatment.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
This study tests if the drug tirzepatide can improve muscle and blood vessel health in older adults with obesity. You may be eligible if you are 50 or older, have a BMI between 30 and 40, and do not have diabetes.
Hear when a new Colorectal Cancer Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.